AN2 Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
AN2 Therapeutics, Inc. (ANTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.88 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.88, a 7.37% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.95, a 63.18% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.58, a 74.90% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $10.28, a 60.37% increase year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.97, a 52.68% decline from fiscal 2024.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.05, a 78.49% decline from fiscal 2023.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $9.53, a 13.60% decline from fiscal 2022.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $11.03.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.88 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $0.88 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $0.97 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $0.97 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.97 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $0.95 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $2.05 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $2.23 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $2.23 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $2.58 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $9.53 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $9.35 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $9.35 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $10.28 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $11.03 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $11.47 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $11.47 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $6.41 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |